Company Overview
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company specializing in antiviral medicines, oncology, and inflammatory diseases, founded in 1987 and headquartered in Foster City, California, trading on Nasdaq (GILD). The company reported approximately $28.6 billion in total revenues for FY2024 under CEO Daniel O'Day, driven by the world's leading HIV treatment franchise anchored by Biktarvy—the world's best-selling antiretroviral therapy with over $14 billion in annual global sales—along with Veklury (remdesivir) for COVID-19 treatment, and a growing oncology portfolio including Trodelvy (sacituzumab govitecan, an ADC for breast and bladder cancer), Yescarta, and Tecartus (CAR-T cell therapies). Gilead's 2024 HIV prevention breakthrough—lenacapavir, a twice-yearly injection preventing HIV infection with near-100% efficacy in large clinical trials—represents potentially the most important HIV prevention advance since the development of daily oral PrEP.
Business Model & Competitive Advantage
The PURPOSE 1 and PURPOSE 2 clinical trials of lenacapavir (subcutaneous injection every 6 months) for HIV Pre-Exposure Prophylaxis demonstrated efficacy rates exceeding 99% in preventing HIV acquisition in high-risk populations—including cisgender women in sub-Saharan Africa and men who have sex with men globally—positioning lenacapavir as a transformative tool in global HIV elimination efforts. The World Health Organization's accelerated review and Gilead's commitment to generic licensing agreements for low-income countries signal lenacapavir's potential for broad global deployment. In oncology, Trodelvy's expansion into non-small cell lung cancer (NSFC), urothelial cancer, and HR+/HER2- metastatic breast cancer builds on its initial 2021 accelerated approval, while Yescarta competes with Bristol-Myers Squibb's Breyanzi in diffuse large B-cell lymphoma CAR-T therapy.
Competitive Landscape 2025–2026
In 2025-2026, Gilead faces HIV revenue pressure from long-acting treatment competition: ViiV Healthcare (GlaxoSmithKline-controlled) markets Cabenuva, a once-monthly injectable HIV treatment, and additional long-acting competitive options in development. Biktarvy faces eventual generic competition as composition-of-matter patents expire in the 2033-2036 timeframe. The oncology pipeline—TROP2 ADC Trodelvy, CAR-T therapies, and novel inflammatory disease assets—must become proportionally more significant as HIV growth moderates. Gilead's balance sheet, supported by strong HIV cash generation, enables continued M&A investment, following the $4.3 billion acquisition of CymaBay Therapeutics (primary biliary cholangitis) in 2024 and the $21 billion Immunomedics deal that brought Trodelvy.
The Gilead Sciences Story
Founders
Company Timeline
Major milestones in Gilead Sciences's journey
Leadership Team
Meet the leaders behind Gilead Sciences
Daniel O'Day
Daniel O'Day joined Gilead as CEO in March 2019 after more than three decades at Roche Pharmaceuticals, where he served as CEO and member of Roche's Corporate Executive Committee. He holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University, and serves on the boards of PhRMA and Galapagos NV.
Andrew Dickinson
Andrew Dickinson has served as CFO since 2016, bringing extensive experience in corporate development, mergers and acquisitions, and financial strategy. He has been instrumental in executing Gilead's major acquisitions including the $11.9 billion Kite Pharma deal and the $4.3 billion CymaBay acquisition.
Johanna Mercier
Johanna Mercier joined Gilead in 2019 from Bristol-Myers Squibb, bringing deep expertise in commercial strategy and operations. She oversees the company's global commercial activities and has been key to expanding Gilead's market reach across HIV, hepatitis, and oncology portfolios.
Dr. Dietmar Berger
Dr. Dietmar Berger assumed the Chief Medical Officer role in January 2025, overseeing the company's global clinical development and medical affairs organizations. He brings extensive experience in pharmaceutical research and development of innovative therapies.
Flavius Martin
Flavius Martin leads Gilead's research organization, driving the discovery and development of new therapeutic candidates across the company's core areas of focus including antivirals, oncology, and inflammatory diseases.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Gilead Sciences is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $28600M in revenue, Gilead Sciences operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Gilead Sciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Gilead Sciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Gilead Sciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Gilead Sciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →